Last reviewed · How we verify
Hyperpolarized Xe129
Hyperpolarized Xe129 is a magnetic resonance imaging (MRI) contrast agent that enhances the visibility of tumors and other lesions.
Hyperpolarized Xe129 is a magnetic resonance imaging (MRI) contrast agent that enhances the visibility of tumors and other lesions. Used for Diagnosis and monitoring of cancer.
At a glance
| Generic name | Hyperpolarized Xe129 |
|---|---|
| Also known as | HP Xenon, 129Xe, Xenon MRI, 129 HXe MRI, Xenon, 129Xe, HP Xenon |
| Sponsor | Mario Castro, MD, MPH |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 2 |
Mechanism of action
It works by exploiting the difference in magnetic properties between hyperpolarized xenon-129 and regular xenon-129, allowing for more detailed imaging of tissues and tumors. This can help doctors diagnose and monitor cancer more accurately.
Approved indications
- Diagnosis and monitoring of cancer
Common side effects
Key clinical trials
- Developing Hyperpolarized Gas MRI Signatures to Detect and Manage Acute Cellular Rejection (PHASE2)
- Dissolved Phase HXe-129 MRI: A Novel Biomarker to Quantify Pulmonary Pathology (PHASE2, PHASE3)
- Xenon-129 and Inert Fluorinated Gas Lung MRI: Study of Healthy Volunteers and Participants With Pulmonary Disease (PHASE2)
- Hyperpolarized Xenon-129 Magnetic Resonance Imaging in Lung Cancer Patients Receiving Radiation Therapy for Investigating Radiation-response and Toxicity (PHASE1)
- 129Xe MRI Cardiopulmonary (PHASE2)
- Non-contrast Lung Perfusion Mapping Applied for New Insights in Cystic Fibrosis (PHASE4)
- Functional Lung Avoidance Radiation Therapy Using Hyperpolarized Xenon-129 MRI (PHASE1)
- Hyperpolarized Xenon Functional Lung Imaging in COPD Patients Undergoing Targeted Lung Denervation
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Hyperpolarized Xe129 CI brief — competitive landscape report
- Hyperpolarized Xe129 updates RSS · CI watch RSS
- Mario Castro, MD, MPH portfolio CI